

Amendments to the Claims:

Kindly amend claim 13, and add new claims 25-27 as follows. The following listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1-12. Canceled.

13. (Currently amended) A method of treating chronic allograft rejection in an allograft recipient in need of such treatment comprising administering cyclosporin A and 2-chlorodeoxyadenosine to the allograft recipient in a coordinated dosage regime comprising days on which both cyclosporin A and 2-chlorodeoxyadenosine are administered and days on which only cyclosporin A is administered,

wherein the coordinated dosage regime comprises administration of 2-chlorodeoxyadenosine in one or more doses over a period of three weeks, and administration of cyclosporin A in at least two equal daily doses per week for a period of three weeks; and repeating the coordinated dosage regime over a treatment period of at least 90 days.

14. (Previously presented) The method according to claim 13 wherein about one to about 16 milligrams of cyclosporin A per kilogram of recipient body mass per day and about 0.5 to about 3 milligrams of 2-chlorodeoxyadenosine per kilogram of recipient body mass per week is administered.

15. Cancelled.

16. (Previously presented) The method according to claim 13 wherein the dosing regime for cyclosporin A is between about 7 and about 112 mg per kilogram of recipient body mass per week.

17. (Previously presented) The method according to claim 13 wherein the dosing regime for cyclosporin A is about 5 mg per kilogram of recipient body mass per day for about two weeks followed by about 5 mg per kilogram of recipient body mass about three times per week.

18. (Previously presented) The method according to claim 13 wherein the dosing regime for 2-chlorodeoxyadenosine is a single dose administered about once per week.

19. Cancelled.

20. (Previously presented) The method according to claim 13 wherein the dosing regime for 2-chlorodeoxyadenosine is a daily dose administered for 1 day to 3 consecutive days during a period of about 7 to about 21 days.

21. Cancelled.

22. (Previously presented) The method according to claim 13 wherein the dosing regime for 2-chlorodeoxyadenosine is about 1.5 to about 3 mg per kilogram of recipient body mass per three weeks.

23. Cancelled.

24. (Previously presented) The method according to claim 13 wherein the mode of administration of cyclosporin A and 2-chlorodeoxyadenosine is subcutaneously, orally, or intravenously.

25. (New) The method according to claim 13 wherein the dosing regime comprises administration of cyclosporin A in at least three doses per week and administration of 2-chlorodeoxyadenosine in a once a week dose.

26. (New) The method according to claim 13 wherein the dosing regime comprises administration of cyclosporin A in at least three doses per week and administration of 2-chlorodeoxyadenosine in at least three doses over a period of three weeks.

27. (New) The method according to claim 26 wherein the dosing regime comprises administration of cyclosporin A in at least three doses per week and administration of 2-chlorodeoxyadenosine in an interval of three consecutive daily doses once every three weeks.